MK-6482-015
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma , Pancreatic Neuroendocrine Tumor , Von Hippel-Lindau Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor , or Solid Tumors With HIF-2α Related Genetic Alterations
Recruiting
Trial purpose
This is a study to evaluate the efficacy and safety of belzutifan monotherapy in participants with advanced pheochromocytoma/paraganglioma (PPGL), pancreatic neuroendocrine tumor (pNET), von Hippel-Lindau (VHL) disease-associated tumors, advanced wt (wild-type) gastrointestinal stromal tumor (wt GIST), or advanced solid tumors with hypoxia inducible factor-2 alpha (HIF-2α) related genetic alterations. The primary objective of the study is to evaluate the objective response rate (ORR) of belzutifan per response evaluation criteria in solid tumors version 1.1 (RECIST 1.1) by blinded independent central review (BICR).
View full trial information on Clinicaltrials.govNATIONAL TRIAL REFERENCE NUMBER
NCT04924075
When you talk with your doctor or clinical trial team member, please have the national trial reference number available.
Eligibility
Only a qualified healthcare professional can determine if you are eligible to take part in a clinical trial. However, this information may be useful in starting a conversation with your doctor.
Conditions
Advanced Gastrointestinal Stromal Tumor, HIF-2α Mutated Cancers, Pancreatic Neuroendocrine Tumor, Pheochromocytoma/Paraganglioma, Von Hippel-Lindau Disease
Age Range
12+
Sex
Male/Female
About the trial
All patients who enroll in the trial will receive medication while on the study.
100% will receive Belzutifan
Current trial Phase
Phase 2
Tests the medicine or vaccine in approximately 100 to 500 participants. In the case of medicines, participants usually have the disease or condition the investigational medicine is designed to treat. In vaccine trials, the participants are usually healthy. Phase 2 trials may happen in a doctor’s office, a clinic, or a hospital.
Trial start and end dates
- Trial start date 08-12-2021
- Estimated primary completion date 06-04-2029
- Estimated trial completion date 06-04-2029
Trial Locations
Locations shown may have changed in some cases. Please call the number listed in the location results to confirm the nearest trial site. Talk with a trial site member for more information.